Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Backlog of orders refers to the quantity and combined monetary value of the products which have been ordered by customers but which have not shipped yet.
The historical rank and industry rank for Omnicell's Order Backlog for Technology (USD Mil) or its related term are showing as below:
FRA:OC9's Order Backlog for Technology (USD Mil) is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: * Ranked among companies with meaningful Order Backlog for Technology (USD Mil) only.
Omnicell (FRA:OC9) Order Backlog for Technology (USD Mil) Explanation
The term backlog refers to a buildup of work that has not yet been completed by the company. The presence of a backlog can have positive or negative implications. For example, a rising backlog of product orders might indicate rising sales. On the other hand, companies generally want to avoid having a backlog as it could cause (or be a result of) increasing inefficiency in the production process. Likewise, a falling backlog might be a sign of lagging demand but could also be a result of improving production efficiency. Naturally, unexpected backlogs can compromise forecasts and production schedules.
Omnicell Order Backlog for Technology (USD Mil) Related Terms
Omnicell Order Backlog for Technology (USD Mil) Historical Data
* Premium members only.
The historical data trend for Omnicell's Order Backlog for Technology (USD Mil) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell Order Backlog for Technology (USD Mil) Chart
What does a Order Backlog for Technology (USD Mil) of 0.00 mean?
Omnicell (FRA:OC9) has a Order Backlog for Technology (USD Mil) of 0.00 as of . 20. Backlog of orders refers to the quantity and combined monetary value of the products which have been ordered by customers but which have not shipped yet. View historical data on Omnicell and its competitors.
Is Omnicell's Order Backlog for Technology (USD Mil) too high?
Omnicell's current Order Backlog for Technology (USD Mil) is 0.00. Overall, Omnicell has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's Order Backlog for Technology (USD Mil) compare to SDGR and OMDA?
Omnicell's Order Backlog for Technology (USD Mil) of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Order Backlog for Technology (USD Mil) for a Healthcare Providers & Services company?
A good Order Backlog for Technology (USD Mil) depends on the Healthcare Providers & Services industry context. However, Order Backlog for Technology (USD Mil) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Order Backlog for Technology (USD Mil) mean?
A high Order Backlog for Technology (USD Mil) can signal that a stock is expensive relative to its fundamentals. Backlog of orders refers to the quantity and combined monetary value of the products which have been ordered by customers but which have not shipped yet. View historical data on Omnicell and its competitors. Omnicell's current Order Backlog for Technology (USD Mil) is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (FRA:OC9) has a current Order Backlog for Technology (USD Mil) of 0.00. The stock's GF Value™ is €32.54, compared to a current price of €27.80 — trading 14.6% below its estimated fair value. The current Order Backlog for Technology (USD Mil) is 0.00. Omnicell's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Order Backlog for Technology (USD Mil) calculated?
Order Backlog for Technology (USD Mil) is calculated from a company's financial statements. For Omnicell (FRA:OC9), the current Order Backlog for Technology (USD Mil) is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (FRA:OC9) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be undervalued.
The current stock price of €27.80 is trading 14.6% below its estimated GF Value™ of €32.54.
Key valuation signals for FRA:OC9:
Order Backlog for Technology (USD Mil): 0.00
GF Value™: €32.54 vs. price of €27.80 (14.6% below fair value)
No single metric tells the full story. See the FRA:OC9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc. is a US-based healthcare technology company that provides medication management and supply chain automation for healthcare providers. Its product portfolio includes automated dispensing cabinets, central pharmacy automation systems, sterile compounding robots, and medication adherence packaging, along with software platforms for inventory control, analytics, and patient engagement. These offerings serve hospitals, health systems, retail pharmacies, long-term care facilities, and other care settings, helping pharmacists and nurses reduce manual tasks and improve medication safety. Omnicell generates revenue primarily through the sale and lease of hardware and software systems, combined with recurring service, maintenance, and subscription-based software fees. The company's largest market is the United States, which accounts for the majority of its revenue, with additional operations in Europe, the Middle East, Asia-Pacific, and other international regions.
78GF Score
Get the complete analysis for FRA:OC9
Order Backlog for Technology (USD Mil) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OC9 has been successfully added to your 
